David Denton, CFO and EVP of Pfizer (PFE): “Our overall solid first-quarter performance demonstrates our continued focus on commercial execution amid U.S. Medicare Part D headwinds. Our focus on operational efficiency and financial discipline is driving strong results to our bottom line. We are currently trending towards the upper end of our 2025 Adjusted diluted EPS guidance range.”
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on PFE:
- Options Volatility and Implied Earnings Moves Today, April 29, 2025
- Pfizer reports Q1 adjusted EPS 92c, consensus 68c
- Pfizer backs FY25 adjusted EPS view $2.80-$3.00, consensus $2.95
- Pfizer: Current guidance assumes no share repurchases in 2025
- Pfizer’s Financial Outlook: Hold Rating Amidst Short-Term Challenges and Long-Term Potential